Literature DB >> 22201186

Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms.

Benoît Marchand1, Isabelle Tremblay, Sébastien Cagnol, Marie-Josée Boucher.   

Abstract

Recent evidences suggest that the activity of glycogen synthase kinase-3 (GSK3) contributes to the tumorigenic potential of pancreatic cancer cells through modulation of cell proliferation and survival. However, further investigations are needed to identify GSK3-dependent mechanisms involved in the control of pancreatic cancer cell proliferation and survival. This study was undertaken to provide further support for a role of GSK3 in pancreatic cancer cell growth as well as to identify new cellular and molecular mechanisms involved. Herein, we demonstrate that prolonged inhibition of GSK3 triggers an apoptotic response only in human pancreatic cancer cells but not in human non-transformed pancreatic epithelial cells. We show that prolonged inhibition of GSK3 activity increases Bim messenger RNA and protein expressions. Moreover, we provide evidence that activation of the c-jun N-terminal kinase (JNK) pathway is necessary for the GSK3 inhibition-mediated increase in Bim expression and apoptotic response. Finally, we demonstrate that concomitant inhibition of GSK3 potentiates the death ligand-induced apoptotic response in pancreatic cancer cells but not in non-transformed pancreatic epithelial cells and that this effect also requires JNK activity. Considering that different approaches leading to stimulation of death receptor signaling are under clinical trials for treatment of unresectable or metastatic pancreatic cancer, inhibition of GSK3 could represent an attractive new avenue to improve their effectiveness.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22201186     DOI: 10.1093/carcin/bgr309

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  27 in total

1.  Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.

Authors:  Benoît Marchand; Dominique Arsenault; Alexandre Raymond-Fleury; François-Michel Boisvert; Marie-Josée Boucher
Journal:  J Biol Chem       Date:  2015-01-05       Impact factor: 5.157

2.  Lithium chloride and inhibition of glycogen synthase kinase 3β as a potential therapy for serous ovarian cancer.

Authors:  Akiva P Novetsky; Dominic M Thompson; Israel Zighelboim; Premal H Thaker; Matthew A Powell; David G Mutch; Paul J Goodfellow
Journal:  Int J Gynecol Cancer       Date:  2013-02       Impact factor: 3.437

Review 3.  Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.

Authors:  Jaewon Lee; Dong-Gyu Jo; Daeui Park; Hae Young Chung; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

4.  GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.

Authors:  Deepali Bang; Willie Wilson; Meagan Ryan; Jen Jen Yeh; Albert S Baldwin
Journal:  Cancer Discov       Date:  2013-04-01       Impact factor: 39.397

Review 5.  Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer.

Authors:  Li Ding; Daniel D Billadeau
Journal:  Expert Opin Ther Targets       Date:  2020-03-21       Impact factor: 6.902

6.  Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy.

Authors:  Qiang Zhang; Mahaveer S Bhojani; Edgar Ben-Josef; Aaron C Spalding; Rork Kuick; Yi Sun; Meredith A Morgan
Journal:  J Carcinog Mutagen       Date:  2013-08-16

Review 7.  Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

8.  Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1.

Authors:  Chengming Fan; Yasin Oduk; Meng Zhao; Xi Lou; Yawen Tang; Danielle Pretorius; Mani T Valarmathi; Gregory P Walcott; Jinfu Yang; Philippe Menasche; Prasanna Krishnamurthy; Wuqiang Zhu; Jianyi Zhang
Journal:  JCI Insight       Date:  2020-06-18

9.  Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway.

Authors:  Zhonglu Peng; Zhengyu Ji; Fang Mei; Meiling Lu; Yu Ou; Xiaodong Cheng
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

10.  GSK3β mediates pancreatic cancer cell invasion in vitro via the CXCR4/MMP-2 Pathway.

Authors:  Xu Ying; Li Jing; Shijie Ma; Qianjun Li; Xiaoling Luo; Zhenguo Pan; Yanling Feng; Pan Feng
Journal:  Cancer Cell Int       Date:  2015-07-05       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.